Spero Therapeutics Culture d’entreprise

Ms. Cristina Larkin has been Chief Operating Officer of Spero Therapeutics, LLC and Spero Therapeutics, Inc. since September 2017. Ms. Larkin served as the Chief Commercial Officer at Spero Therapeutics, Inc., from March 2, 2016 to September 2017. Ms. Larkin has over 22 years of experience developing strategic commercial insights for biopharmaceutical companies from Phase 1 studies to product launch. Her expertise ranges across various infectious disease products, including Avycaz, Dalvance, Teflaro, Levaquin and Floxin. Prior to joining Spero, she served as an Assistant Vice President for Forest Laboratories. There, she led the commercial hospital antibiotic franchise team and was responsible for the U.S. launch and execution strategy for several antibiotics. Before joining Forest Laboratories, She also held a variety of commercial roles at Ortho-McNeil Pharmaceutical, a division of Johnson and Johnson, that included sales, managed markets, reimbursement and marketing. She played an integral role in the out-licensing of ceftaroline to AstraZeneca, the acquisition of Durata and more. Ms. Larkin received a Bachelor's Degree from Florida State University.

Mr. Joel D. Sendek has been the Chief Financial Officer of Spero Therapeutics, Inc. since May 22, 2017 and serves as its Principal Accounting Officer. Mr. Sendek has been the Chief Financial Officer of Spero Therapeutics, Llc since May 22, 2017. He served as the Chief Financial Officer of Forward Pharma A/S since August 5, 2014 until April 30, 2017 and served for over 17 years as a senior equity research analyst covering biotechnology. As an analyst, he served as a Managing Director at Stifel Financial Corp. Mr. Sendek served as the Managing Director at Stifel, Nicolaus & Company, Incorporated, Research Division and served as its Biotechnology Analyst since 2012. He joined the Stifel, Nicolaus & Company in 2012. Mr. Sendek has more than 20 years of experience in the life sciences sector and is widely recognized in the investment community and the corporate world for his broad biotechnology expertise and proprietary insight, including a previous #1 ranking for Stock Picking in The Wall Street Journal's Best on the Street Survey. He served as the Managing Director and Biotechnology Analyst for 12 years at Lazard Capital Markets LLC, Research Division, where he established Lazard's healthcare equity research effort in 2000. He served as Senior Vice President and Biotechnology Research Analyst at Gerard Klauer Mattison and served as an Equity Analyst at BMO Capital Markets U.S. From 1992 to 1997, he served as Senior Director of Corporate Development at Progenics Pharmaceuticals, where he negotiated corporate partnerships, raised private equity capital and prepared the Progenics for an IPO. Prior to Progenics, Mr. Sendek worked in the corporate finance department and Investment Banking Analyst at Goldman, Sachs & Co., focused on healthcare, from 1989 to 1992. He was recognized by the Wall Street Journal as an All-Star Analyst with a #1 ranking for stock picking in biotechnology as well as first place in the Home Run Hitter category among all sectors. Mr. Sendek received a Bachelor of Arts in Biochemistry from Rice University.

Dr. Thomas R. Parr, Jr., also known as Tom, Ph.D., has been Chief Scientific Officer at Spero Therapeutics, Inc. since April 2014. Dr. Parr serves as Chief Scientific Officer of Spero Therapeutics, LLC. Dr. Parr served as Chief Scientific Officer of Fedora Pharmaceuticals Inc. He served as Chief Scientific Officer of Targanta Therapeutics Inc. (formerly, Phagetech) since January 2005 and also as its Montreal Site Head since December 2007. From May 2003 to December 2004, Dr. Parr served as Vice President of Research of Adaptive Therapeutics, Inc. Dr. Parr joined Adaptive Therapeutics in 2003 and accomplished a series of scientific milestones as well as reorganizing and restructuring research efforts. While at Targanta, he was instrumental in progressing the lipoglycopeptide, oritavancin through to registration meetings with the FDA and EMA. Dr. Parr has worked on a broad range of marketed and experimental antibiotics including beta-lactams (cefaclor, loracarbef, cefuroxime axetil, cephalexin, moxalactam, ceftazidime, cefazolin, RWJ-333441); glycopeptides (vancomycin and oritavancin); lipodepsipeptides (daptomycin); aminoglycosides (tobramycin); quinolones (cinoxacin); macrolides (dirythromycin); and antimicrobial peptides (iseganins). From May 2002 to May 2003, Dr. Parr served in various capacities at Embiosis Pharmaceuticals, (formerly MicroGenomics, Inc.), a private biopharmaceutical company, as its President and acting Chief Executive Officer. Dr. Parr served as Vice President of Research and Development of Embiosis Pharmaceuticals. He served as Senior Director of Microbiology of Xenogen Corporation from August 2001 to March 2002. From May 2000 to August 2001, Dr. Parr served as Senior Director of Microbiology at Intrabiotics Pharmaceuticals, Inc., a private biopharmaceutical company. Dr. Parr has more than 25 years drug discovery experience across both large pharmaceutical and small biotechnology companies. From 1997 to 2000, Dr. Parr served as a Senior Microbiologist at Lilly. During his career, Dr. Parr has been involved in the development of several marketed and late-stage clinical candidates for both antibacterial and antifungal applications. He worked at Microcide. He serves as Member of Scientific Advisory Board of Medisyn Technologies, Inc. He was an Assistant Professor in the Department of Microbiology and Biochemistry at the University of Ottawa before beginning his drug discovery and development career. Dr. Parr received a Ph.D. degree in Microbiology and Infectious Diseases from The University of Calgary, a M.A. in Philosophy from the University of Calgary and a B.A. in Biology and Philosophy from the University of Minnesota. He conducted an MRC postdoctoral fellowship at the University of British Columbia.

Tim Keutzer serves as the Senior Vice President of Spero Therapeutics. Tim started at Spero Therapeutics in Aug of 2015. Tim currently resides in the Greater Boston Area.

Ian Critchley serves as the Vice President, Head of Clinical Microbiology of Spero Therapeutics. Ian started at Spero Therapeutics in April of 2018. Ian currently resides in the Greater Boston Area.

Stephen Garbacz serves as the SVP Finance and Operations of Spero Therapeutics. Stephen started at Spero Therapeutics in July of 2015. Stephen currently resides in the Greater Boston Area.

Troy Lister serves as the Vice President Research of Spero Therapeutics. Troy started at Spero Therapeutics in September of 2014. Troy currently resides in the Greater Boston Area.

David Melnick serves as the Chief Medical Officer of Spero Therapeutics. David started at Spero Therapeutics in January of 2018. David currently resides in the Greater New York City Area.